New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 4, 2013
16:46 EDTREGNRegeneron recommends rejection of mini-tender offer by TRC Capital
Regeneron Pharmaceuticals (REGN) has been notified of an unsolicited "mini-tender" offer by TRC Capital to purchase up to 1M shares, or approximately 1.06%, of the outstanding Regeneron common stock at a price of $161.25 per share. TRC's offer price represents approximately a 4.46% discount to the closing price of Regeneron common stock on December 27, 2012, the last closing price prior to commencement of the offer, and a 10.77% discount to the closing price of Regeneron common stock on January 3, 2013. In addition, TRC's offer is subject to numerous conditions, including the availability of financing satisfactory to TRC. Regeneron does not endorse TRC's offer and recommends that shareholders do not tender their shares in response to the offer because it is a so-called "mini-tender" offer at a price below the current market price for Regeneron shares and is subject to numerous conditions. Regeneron urges shareholders considering TRC's offer to obtain current market quotations for their shares, review the conditions to the offer, consult with their broker or financial adviser and exercise caution with respect to TRC's offer. Regeneron is not associated in any way with TRC, its mini-tender offer or the offer documentation. According to TRC's current offer documents, Regeneron shareholders who have tendered their shares may withdraw their shares at any time prior to 12:01 a.m., New York City time, on Tuesday, January 29, 2013, the expiration date set forth in the offer documents (unless extended), by following the procedures described in the offer documents.
News For REGN From The Last 14 Days
Check below for free stories on REGN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 18, 2014
07:57 EDTREGNCambridge Healthtech Institute to hold a summit
6th Annual Bioprocessing Summit to be held in Boston on August 18-22.
August 11, 2014
07:07 EDTREGNRegeneron reports Q2 EPS 9c, consensus 6c
Subscribe for More Information
05:32 EDTREGNRegeneron Eylea injection receives EU approval for DME treatment
Subscribe for More Information
August 7, 2014
17:12 EDTREGNRegeneron reports 8.1% passive stake in Avalanche Biotechnologies
Subscribe for More Information
August 6, 2014
08:40 EDTREGNRegeneron price target raised to $373 from $349 at RBC Capital
RBC Capital increased its price target on Regeneron as the firm thinks that the company's Q2 results addressed many of investors' concerns. The firm is upbeat on the company's near-term outlook and keeps an Outperform rating on the shares.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use